Risk assessment for vaccination programmes in a pandemic. A Swedish model for efficacy and safety during COVID-19

Authors

  • Gerhard Wikström Editor, Upsala Journal of Medical Sciences
  • Michael Welsh Editor, Upsala Journal of Medical Sciences

DOI:

https://doi.org/10.48101/ujms.v130.13602

Downloads

Download data is not yet available.

References

1. Zethelius B, Rubin J, Pihlström N, Liminga UW, Back H, Aronsson B, et al. Overview of approved COVID-19 vacines in the EU, recommendations for use in Sweden and vaccine uptake over time. Report from the Swedish Medical Products Agency and the Public Health Acency of Sweden. Ups J Med Sci. 2025;130:e12937. doi: https://doi.org/10.48101/ujms.v130.12937

2. Buonocore SM, van der Most RG. Narcolepsy and H1N1 influenza immunology a decade later: what have we learned? Front Immunol. 2022;13:902840. doi: https://doi.org/10.3389/fimmu.2022.902840

3. Ljung R, Sundstrom A, Grunewald M, Backman C, Feltelius N, Gedeborg R, et al. The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Ups J Med Sci. 2021;126:8136. doi: https://doi.org/10.48101/ujms.v126.8136

Published

2025-11-24

How to Cite

Wikström , G., & Welsh , M. . (2025). Risk assessment for vaccination programmes in a pandemic. A Swedish model for efficacy and safety during COVID-19. Upsala Journal of Medical Sciences, 130, e13602. https://doi.org/10.48101/ujms.v130.13602

Issue

Section

Editorial